COLORADO SPRINGS, CO, UNITED STATES, January 14, 2026 /EINPresswire.com/ -- Lahjavida Bio, a biotechnology company ...

The company joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.

MITOLINE™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory ...

Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative ...

One person's side effect could be another person's treatment if we expand our perspective on small molecule drug targets, according to a new study published November 5, 2025, in npj Precision Oncology ...

DF-003 is the first ALPK1 inhibitor to successfully complete a first-in-human Phase 1 study and has now entered a Phase 1b clinical trial in patients with ROSAH syndrome (NCT06395285), where it is ...

Researchers at Nano Life Science Institute (WPI-NanoLSI) and the Cancer Research Institute at Kanazawa University have ...

Axcelead DDP, a drug discovery solution provider with a strong foundation in pharmaceutical R&D, continues to expand and strengthen its capabilities through both in-house development and strategic ...

Explore the latest advances in fluorescent technology for unmatched clarity in monitoring living cell processes and drug responses.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...